Diseases / Bronchiectasis
Bronchiectasis
DiseaseBronchiectasis is a chronic lung disease characterized by persistent, irreversible dilation of the bronchial airways with impaired mucociliary clearance. It is associated with recurrent infection, mucus retention, chronic cough, and progressive respiratory morbidity.
- Trials
- 329
- Recruiting
- 59
- Completed
- 135
- With results
- 29
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | — | 1 | — | — | 1 | 2 |
| Phase 1 | 1 | — | — | — | 5 | 3 | — | — | 1 | 10 |
| Phase 1/2 | 1 | — | — | — | 4 | — | — | — | 1 | 6 |
| Phase 2 | 2 | 2 | 1 | 1 | 14 | 5 | — | 1 | 4 | 30 |
| Phase 3 | 1 | 3 | — | — | 15 | 4 | — | — | 3 | 26 |
| Phase 4 | 5 | 1 | — | — | 14 | 2 | 1 | — | 8 | 31 |
| Not applicable | 15 | 8 | — | 1 | 51 | 5 | — | 1 | 23 | 104 |
| Unknown | 34 | 5 | 1 | 4 | 32 | 2 | 2 | 1 | 39 | 120 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bronchiectasis | 2 | 10 | 6 | 30 | 26 | 31 | 104 | 120 | 329 |
| Pulmonary Disease, Chronic Obstructive | 1 | — | — | 3 | — | 4 | 16 | 37 | 61 |
| Asthma | 1 | 1 | — | 2 | — | 1 | 11 | 24 | 40 |
| Cystic Fibrosis | 1 | 3 | — | 3 | 2 | 1 | 13 | 11 | 34 |
| Lung Diseases, Interstitial | 1 | 1 | — | — | — | — | 6 | 9 | 17 |
| Lung Diseases | — | 1 | — | 3 | 2 | — | 1 | 7 | 14 |
| Pseudomonas Infections | — | 1 | — | 2 | 1 | 4 | 1 | 3 | 12 |
| Lung Neoplasms | 1 | — | — | — | — | — | 4 | 6 | 11 |
| Pulmonary Fibrosis | 1 | 1 | — | — | — | — | 6 | 2 | 10 |
| Emphysema | 1 | 1 | — | — | — | — | 4 | 2 | 8 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Assiut University | 14 | 1 |
| 2 | Shanghai Pulmonary Hospital, Shanghai, China | 13 | 0 |
| 3 | Bayer | 6 | 2 |
| 4 | Hacettepe University | 6 | 0 |
| 5 | The First Affiliated Hospital of Guangzhou Medical University | 6 | 0 |
| 6 | First Affiliated Hospital of Ningbo University | 5 | 0 |
| 7 | Guangzhou Institute of Respiratory Disease | 5 | 1 |
| 8 | Imperial College London | 5 | 0 |
| 9 | Ruijin Hospital | 5 | 0 |
| 10 | Syntara | 5 | 2 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Azithromycin | 9 |
| 2 | Ciprofloxacin | 5 |
| 3 | Saline Solution, Hypertonic | 5 |
| 4 | Sodium Chloride | 5 |
| 5 | Exercise | 4 |
| 6 | Roflumilast | 4 |
| 7 | Bronchoalveolar Lavage | 3 |
| 8 | Bronchoscopy | 3 |
| 9 | Chest Wall Oscillation | 3 |
| 10 | Inhalation | 3 |
Evidence
- Results reported
- 21.5%29 of 135 completed
- Published
- 21.5%29 of 135 completed
- Primary endpoint met
- 52.4%11 of 21 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 76
- Median duration
- 25.7months
- Countries
- 53
- Study sites
- 2182
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 23
- Phase 1
- 36
- Phase 1/2
- 18
- Phase 2
- 89
- Phase 3
- 245
- Phase 4
- 71
- Not applicable
- 46
- Unknown
- 150
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Shanghai | China | 31 |
| 2 | London | United Kingdom | 26 |
| 3 | Guangzhou | China | 20 |
| 4 | Barcelona | Spain | 19 |
| 5 | Cambridge | United Kingdom | 18 |
| 6 | Tyler | United States | 18 |
| 7 | Istanbul | Turkey (Türkiye) | 17 |
| 8 | New York | United States | 17 |
| 9 | Edinburgh | United Kingdom | 16 |
| 10 | Hanover | Germany | 15 |
Terminations
- Terminated
- 22
- Withdrawn
- 3
- Suspended
- 3
- Stopped for recruitment
- 1.2%4 of 329 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04843345 Suspended | Suspended | Indefinite paused for staffing issues | 2030-04-01 |
| NCT07547436 Suspended | Suspended | The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity. | 2029-05-11 |
| NCT00001223 Terminated | Terminated | PI left NIH | 2026-01-30 |
| NCT04266873 Suspended | Suspended | Data analysis review of current data | 2025-12-31 |
| NCT06418711 Terminated | Terminated | Futility | 2025-11-10 |
| NCT03696290 Terminated | Terminated | Poor recruitment | 2025-03-04 |
| NCT03737617 Withdrawn | Withdrawn | Cant obtain IMP | 2024-12-01 |
| NCT04017312 Terminated | Terminated | Data | 2024-08-06 |
| NCT04616924 Terminated | Terminated | extremely slow enrollment into study | 2023-08-28 |
| NCT04396366 Terminated | Terminated | Strategic business decision | 2023-06-21 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: